For the mass vaccination of Ukrainians, the drug is currently unavailable - it has not yet been delivered.
This is a vector vaccine based on the common cold virus. The drug contains a rendered harmless human adenovirus, into which the DNA encoding the virus protein is embedded. This drug bears similarities to AstraZeneca. Both concentrate on a spike protein on the surface of the virus, triggering an immune response.
The vaccine should only be given once intramuscularly. Therefore, more people can get faster access to the drug.
Contains the following ingredients: recombinant, non-replicating adenovirus type 26 expressing the SARS-CoV-2 spike protein, citric acid monohydrate, trisodium citrate dihydrate, ethanol, 2-hydroxypropyl-β-cyclodextrin (HBCD), polysorbate-80, sodium chloride ... If you are allergic to one of these ingredients, vaccination is not recommended.
Another plus - the drug needs a storage temperature of +2 to +8 degrees. For example, Pfizer needs a so-called super cold - up to -80 degrees.
The vaccine can be offered to people who have previously had Covid-19. However, they can, if they wish, postpone vaccination for up to six months from the time of infection.
This vaccine can also be offered to women during the breastfeeding period if they belong to the category of the population recommended for vaccination (for example, they work in the health sector).
On July 1, 2021, a new report on the effectiveness of the vaccine appeared. Research data confirms that one vaccination provides immune protection against coronavirus for eight months.
The company also said the vaccine protects against the new Delta strain of the coronavirus.
Earlier, the World Health Organization called the following figures:
- the effectiveness of protection against moderate and severe symptoms of the disease as a result of infection was estimated at 66.9%.
- the effectiveness of protection against severe disease and the need for hospitalization after 28 days after vaccination is 85.4%.
Patients may experience the following standard short-term side effects:
- pain, skin redness, and swelling at the injection site;
- feeling very tired;
- muscle pain;
There are also symptoms that may indicate a severe allergy (as a rule, they become known during the standard 15-30 minute observation period in the doctor's office):
- labored breathing;
- swelling of the face and throat;
- heart palpitations;
- profuse rash all over the body;
- dizziness and weakness.
The European Medicines Agency (EMA) has recommended adding platelet-lowering blood clots to the list of very rare adverse reactions (about 7 per million) for this drug. In most cases, blood clots and low platelet counts were observed in women between the ages of 18 and 49. The benefits of the drug outweigh the risks.
Symptoms of rare type blood clots include:
- chest pain;
- swelling of the legs;
- prolonged abdominal pain;
- severe or prolonged headache;
- blurred vision;
- easy bruising;
- small red dots under the skin outside the injection site.
In the United States, some states discontinued use in April due to nausea and dizziness in patients. In Colorado, 11 people have had adverse reactions, and in North Carolina, 18 people have experienced adverse reactions. Six vaccinated in the United States were diagnosed with a rare blood clot disease.
One of the advantages of the drug is that it is approved in the EU and other Western countries. Thus, the Janssen vaccine is one of four certified in the European Union. It is also used in the USA, UK, Switzerland, Canada.
The drug manufactured by Johnson & Johnson is approved for emergency use by the World Health Organization (WHO).
When to expect next?
Currently, only one case of vaccine import into our country is known. At the end of May, 500 doses of the Janssen vaccine were brought to Ukraine. It was allowed to be imported for a private company, which ordered, paid for, and organized the delivery of the vaccine.
Employees of this firm work in the fishing industry in Alaska in the United States. To enter America, it was necessary to be vaccinated with a vaccine certified in the States.
In addition, there were negotiations on the supply of the vaccine. This was announced at the end of June by the head of the parliamentary committee on the health of the nation Mykhailo Radutsky.